Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Campath-based Allo SCT for Hemoglobinopathies and Bone Marrow Failure
NCT00004143Phase 2Completed
- Start
- Sep 1999
- Primary completion
- May 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab in sickle cell anemia (SCA), aplastic anemia, paroxysmal nocturnal hemoglobinuria (PNH) and 1 more. Primary endpoints: Number of Patients With Neutrophil Engraftment at 1 year, Number of Patients With Platelet Engraftment at 1 year and 3 more. Started Sep 1999; status: completed.
02
Drugs
alemtuzumab
03
Conditions
sickle cell anemia (SCA)aplastic anemiaparoxysmal nocturnal hemoglobinuria (PNH)pure red cell aplasia (PRCA)
Beyond the preview
Go deeper on NCT00004143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004143.